TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05699733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction for knee joint
Description: All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction for knee joint
Description: All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction for knee joint
Description: All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
Study: NCT04780568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: Given IV
Study: NCT05109299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak toothpaste
Description: Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: 1450 ppm fluoride toothpaste
Study: NCT05071118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
Study: NCT05777642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxygen Nanobubble
Description: This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen Nanobubble
Description: This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
Study: NCT06176196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration.
Study: NCT06071962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap (AP707)
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT06530758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered ASRS format, without shading and with grouping
Description: Participants will be asked to complete the ASRS form without shading and with grouping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered ASRS format, with shading and without grouping
Description: Participants will be asked to complete the ASRS form with shading and without grouping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered ASRS format, without shading and without grouping
Description: Participants will be asked to complete the ASRS form without shading and without grouping.
Study: NCT06229145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral
Study: NCT04843865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese Herbs
Description: Chinese Herbs
Study: NCT05273723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Behavioral Change Techniques
Description: 1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: You planned to walk today in the park at 3pm.
Study: NCT05155865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resynchronization with conduction system pacing
Description: Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy with biventricular stimulation
Description: Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
Study: NCT05853848

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postcard
Description: Postcard with phone number to call for help scheduling a mammogram.
Study: NCT05904015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
Description: Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
Description: Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable.
Study: NCT05853848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letter with phone number to call for help scheduling a mammogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto-dialer
Description: Auto-dialer with option to press button for help scheduling a mammogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live call
Description: Live call offering help scheduling a mammogram.
Study: NCT05842395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Participants with distal radius fractures will take vitamin C supplementation with a daily dose of 1g orally for three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants with distal radius fractures will take daily Placebo orally for three months.
Study: NCT04322864

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
Study: NCT04572048

Intervention type: OTHER
Group type: OTHER
Intervention: Single-day NRP Training
Description: NRP training course completed in one single day of 8 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: longitudinal NRP training
Description: NRP training course completed over one year by attending nine 30-minute modules.
Study: NCT05082038

Intervention type: DEVICE
Group type: OTHER
Intervention: Mandibular partial rehabilitation with IF Tapared implants
Description: 2 IF Tapared Implants (Group IF) on one side of the mandible

Intervention type: DEVICE
Group type: OTHER
Intervention: Mandibular partial rehabilitation with CF Tapared implants
Description: 2 CF Tapared Implants (Group CF) on the other side of the mandible
Study: NCT06201338

Intervention type: PROCEDURE
Intervention: Screening of preoperative frailty
Description: The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale
Study: NCT05371496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 3.0 mg/ml (titrated to 2.4 mg) subcutaneous once weekly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo with no active drug once weekly for 12 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counselling on healthy lifestyle intervention
Description: All participants will receive counselling on healthy lifestyle intervention including limiting consumption of salt, red meat, saturated or trans fats, sweets, and sugar-sweetened beverages, and how to restrict calorie intake (500 kcal/day deficit) in consultation with a trained study dietician. Regular physical activity \>150 minutes per week will be encouraged.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling on healthy lifestyle intervention
Description: All participants will receive counselling on healthy lifestyle intervention including limiting consumption of salt, red meat, saturated or trans fats, sweets, and sugar-sweetened beverages, and how to restrict calorie intake (500 kcal/day deficit) in consultation with a trained study dietician. Regular physical activity \>150 minutes per week will be encouraged.
Study: NCT05719454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNT testing
Description: The effect of CNT on blood pressure will be obtained throughout the year long follow up period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNT testing
Description: The effect of CNT on blood pressure will be obtained throughout the year long follow up period.

Intervention type: DEVICE
Group type: OTHER
Intervention: CNT testing
Description: The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
Study: NCT06494293

Intervention type: OTHER
Intervention: Data Collection
Description: Collection of medical data from MICU intervention file and patient medical files from participating centres
Study: NCT05805592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen-to-Move-Program (STEP)
Description: It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP).
Study: NCT06288906

Intervention type: OTHER
Intervention: mechanical thrombectomy of caval and iliofemoral veins
Description: investigate efficacy, safety of mechanical thrombectomy systems used in symptomatic acute and subacute ileofemoral and caval thrombosis
Study: NCT05154279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial terlipressin vs carbitocin vs saline as placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial terlipressin vs carbitocin vs saline as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial terlipressin vs carbitocin vs saline as placebo
Study: NCT05151380

Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 laser MonaLisa Touch ®
Description: 3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice
Study: NCT06354634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin polymer (NuSmile Bioflx) crown
Description: Resin polymer (NuSmile Bioflx)crown

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stainless steel crown
Description: Stainless steel crown
Study: NCT05492682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PeptiCRAd-1
Description: All patients will receive PeptiCRAd-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PeptiCRAd-1
Description: All patients will receive PeptiCRAd-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All patients will be pre-treated with one single dose of Cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All patients will be pre-treated with one single dose of Cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients will receive 6 doses of Pembrolizumab within the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients will receive 6 doses of Pembrolizumab within the study.
Study: NCT05570786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestrinone
Description: The intradermal gestrinone/placebo pellet will be inserted on the same day as the levonorgestrel intrauterine hormonal device (Kyleena®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subdermal implant-bioabsorbable placebo pellet (cholesterol)
Study: NCT05795140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptcaopan 200 mg
Description: Open label, participant specific kits, hard gelatin capsules to be taken twice a day
Study: NCT04322864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
Study: NCT06223958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI (axitinib implant)
Description: Intravitreal Injection of OTX-TKI (axitinib implant)

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Injection of 2mg (0.05mL) of aflibercept
Study: NCT06372769

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyograph and kinesiograph
Description: The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities.

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyograph and kinesiograph
Description: The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities.
Study: NCT06273423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OULA, Mind-body Physical Activity
Description: Group dance fitness program with focus on the mind-body connection
Study: NCT05410938

Intervention type: DRUG
Intervention: Chemotherapy
Description: Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab

Intervention type: DRUG
Intervention: Chemotherapy
Description: Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
Study: NCT05526105

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gastric Ultrasound
Description: Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gastric Ultrasound
Description: Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
Study: NCT04091074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Half of patients undergoing carotid stenting take ticagrelor+aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting
Description: Patients with carotid stenosis will undergo carotid stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting
Description: Patients with carotid stenosis will undergo carotid stenting
Study: NCT06337175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
Study: NCT04301778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-6352
Description: 1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV
Study: NCT06564441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam